| Cat.No. | Name | Information |
|---|---|---|
| M58555 | Volociximab | Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| M58432 | Anti-Mouse RANKL/CD254 Antibody (Clone 7C6) In vivo | Anti-Mouse RANKL/CD254 Antibody (Clone 7C6) is a Mouse-derived VHH-mFc type antibody, targeting to mouse RANKL/CD254. |
| M58370 | Gemtuzumab | Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for the synthesis of antibody-drug conjugate (ADC) Gemtuzumab ozogamicin. |
| M55700 | Anti-human CD52 mAb (HEK293) | |
| M55669 | Anti-Mouse IFNß (interferon beta) Antibody (Clone HDß-4A7) In vivo | Anti-Mouse Interferon-beta (IFN-ß) (Clone HDß-4A7) recognizes an epitope on Mouse IFN-ß and binds specifically to murine IFNß and does not bind murine IFNg or several different IFNa species (a-1,4,5 or 13); HDb-4A7 binds both recombinant and natural forms. |
| M55206 | Lintuzumab | Lintuzumab is a humanized monoclonal antibody directed against CD33, which is expressed on the majority of myeloblasts in acute myeloid leukemia. |
| M55043 | Cinpanemab | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease. |
| M55042 | Cofetuzumab | Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. |
| M55041 | Crizanlizumab | Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs). |
| M54716 | Trontinemab | Trontinemab is a bispecific human IgG1-κ antibody that targets amyloid β A4 precursor protein (APP) and transferrin receptor (TFRC).Trontinemab may be used in Alzheimer's disease-related studies. |
| M54553 | Erfonrilimab | Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4. |
| M54551 | Rademikibart | Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
| M54547 | Enlonstobart | Enlonstobart is a recombinant humanized anti-PD-1 IgG4ҡ monoclonal antibody that can be used for tumor-related studies. |
| M50198 | Pelgifatamab | Pelgifatamab is a monoclonal antibody targeting prostate cancer-specific membrane antigen (PSMA) for prostate cancer-related studies. |
| M49947 | Ifabotuzumab | Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis. |
| M49822 | ANX005 | ANX005 is a monoclonal antibody that blocks the activation of the entire classical signaling pathway by inhibiting complement protein C1q, which is upstream of the complement cascade reaction, while also maintaining the functional integrity of other complement pathways. It can be used in studies related to Guillain-Barre Syndrome (GBS). |
| M49437 | Afimkibart | Afimkibart (PF-06480605) is an IgG1 human monoclonal antibody against TNF-like ligand 1A (TL1A, TNFSF15), which can be used in studies related to ulcerative colitis (UC). |
| M45360 | LYT-200 | Research Grade Anti-Human LGALS9 (LYT-200) is a monoclonal antibody that targets galectin-9 (galectin-9) and has antitumor activity. |
| M45266 | Linvoseltamab | Linvoseltamab is a bispecific antibody targeting BCMA (TNFRSF17) and CD3. Linvoseltamab is used in studies related to relapsed/refractory multiple myeloma (R/R MM). |
| M45249 | DCBY02 | DCBY02 is a monoclonal antibody targeting CD93 for studies related to solid tumors. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
